DOI: https://doi.org/10.36347/sasjm.2025.v11i03.001

Pages: 133-137

The effectiveness, safety and usage of bempedoic acid in controlling hypercholesterolemia and lowering cardiovascular risk are assessed in this systematic review. It comprises of 15 trials evaluating cardiovascular outcomes, adverse events, and improvements in lipid profiles. Bempedoic acid showed significant decrease in non-HDL-C, total cholesterol, LDL-C, and CRP levels. While effective, some studies noted side effects, such as gout flare-ups and elevated uric acid levels. Overall, bempedoic acid is a promising treatment option with manageable safety risks, particularly for statin-intolerant patients. Background: Elevated cholesterol levels is a critical risk factor in cardiovascular disease. While statins are effective, some patients cannot tolerate them due to statin intolerance, necessitating alternative therapies. Bempedoic acid, an innovative oral ATP-citrate lyase inhibitor, has emerged as a viable option. This review synthesizes existing data to evaluate its efficacy and safety in cholesterol management. Method: This review included systematic reviews, meta-analyses, and randomized controlled trials reported between 2019 and 2024. Peer-reviewed studies focused on bempedoic acid's efficacy and safety in various populations. Data were extracted on study design, population characteristics, interventions, and outcomes, including lipid profiles, CRP levels, and MACE. The Cochrane Risk of Bias tool and the Newcastle-Ottawa Scale were used to assess the quality of the study ensuring consistent, reliable data extraction. Result: The systematic review revealed that bempedoic acid efficiently lowers levels of LDL-C, total cholesterol, CRP and non-HDLC; its effectiveness is increased by combination therapy. It considerably decreased the incidence of myocardial infarction and other major adverse cardiovascular events (MACE) in high-risk populations, even though frequent side effects such flare-ups of gout and higher uric acid levels were observed. Conclusion: Bempedoic